Avelumab in G3 NEC

Categoría Estudio primario
Registro de estudiosclinicaltrials.gov
Año 2017
This is a single-center, single-arm, open-label, pilot trial to evaluate the efficacy and safety of avelumab in subjects with unresectable or metastatic, Grade 3, poorly-differentiated neuroendocrine.carcinoma.
Epistemonikos ID: 704dc50bcb326f23ba8e7fdbc8cbb6a25d617971
First added on: May 21, 2024